

Cardiac Implantable Electronic Device **Lead** Infection - Microbiology Full Clinical Guideline

Reference number: CG-ANTI/3475/24

Introduction

- Established cardiac implantable electronic devices (CIED) include permanent pacemakers (PPM), implantable cardioverter-defibrillators (ICD), and cardiac resynchronisation therapy pacemakers (CRT-P).
- In general, PPM, ICD, and CRT-P cardiac devices have:
 - Generators sited in the left anterior chest; and
 - Leads – introduced through the venous vasculature – residing in the atrial or ventricular myocardium.

The electrical stimulus from the generator pocket is transmitted, via the transvenous leads, to the heart.
- CIEDs are emerging – for example, leadless pacemakers and subcutaneous implantable cardioverter-defibrillators – without transvenous leads.
- Established PPM, ICD, and CRT-P cardiac devices – with generators and leads – are the focus of this microbiology clinical guideline.
- The commonest causes of CIED infections are the Gram positive *Staphylococcus* species:
 - Methicillin susceptible or resistant coagulase negative staphylococci, e.g. *Staphylococcus epidermidis*; or
 - Methicillin susceptible or resistant *Staphylococcus aureus*.
- Less commonly isolated pathogens include:
 - Further Gram positive bacteria: *Corynebacterium*, *Cutibacterium*, *Enterococcus*, and *Streptococcus* species.
 - ± Gram negative bacteria.
 - ± Fungi.
- In general, the pathogens of CIED infection are inoculated via:
 - An iatrogenic mechanism of transmission:
 - Contamination of the generator/lead – with host/healthcare professional flora – on implantation/manipulation.
 - Or, a haematogenous mechanism of transmission:
 - Another focus of infection culminates in bloodstream infection; the microorganism disseminates via the blood to inoculate the cardiac device.
- Microbial infection of the leads – manifesting with symptoms and/or signs of infective endocarditis – is termed CIED lead infection.
- Please note that specific hospital guidelines exist for [CIED pocket infection](#).

Differential diagnosis

- Whilst microbial infection of the leads can manifest with infective endocarditis symptoms and signs; equally, the stigmata can be limited to fever only.
- Therefore, if the past medical history includes CIED, and if there are clinical concerns regarding pyrexia of unknown origin, consideration of lead and pocket infection in the differential diagnosis is recommended.
- NB The symptoms and signs of CIED lead infection can also be mimicked by other infective pathologies (e.g. septic thrombophlebitis).

Investigation

- The provision of clinical details is the duty of the requesting physician and is integral to best practice.
- The microbiology department processes thousands of blood cultures annually. The provision of clinical details enable:
 - The biomedical scientists and medical laboratory assistants to process the blood cultures appropriately. For example, with regard to culture, extending the period of incubation – from the standard 5 days – to 10 days. For example, with regard to susceptibilities, performing minimum inhibitory concentration (MIC) testing immediately.
 - The consultant microbiologists to interpret the blood cultures appropriately. For example, communicating coagulase negative staphylococci bacteraemia to physicians re patients with past medical histories of CIEDs.
- The echocardiographers perform thousands of echocardiograms annually. The provision of clinical details enable:
 - The echocardiographers to vet and prioritise requests appropriately.
 - The echocardiographers and cardiologists to interpret the images appropriately.

Blood sciences

- Full blood count (FBC), C reactive protein (CRP), lactate, urea and electrolytes (U&Es), and liver function tests (LFTs).

Microbiology

- Before starting antibiotics:
 - If the patient is clinically stable:
 - Blood cultures x 3; drawn approximately 12 hours apart; from 3 locations/venepunctures.
 - If the patient is clinically unstable (haemodynamic instability, sepsis, or septic shock):
 - Blood cultures x 3; drawn approximately 1-15 minutes apart; from 3 locations/venepunctures.
 - Please provide relevant clinical details:
 - For example: “Fever. Cardiac device. ?Lead/Pocket infection.”
 - NB In CIED lead infection, blood cultures are – in general – positive.
- If purulent discharge:
 - Fluid for microscopy, culture, and susceptibilities (MC&S).
- If medicine/surgery intervenes:
 - If returned to the cath lab or taken to theatre:
 - Pocket swab for MC&S; and
 - Tissue sample for MC&S; and
 - Lead tip for MC&S.

Radiology

- Chest x-ray (CXR).

Echocardiogram, provided by cardiology and Clinical Measurement Department

- Clinical suspicions of CIED infection – emanating from physicians and/or pathologists – warrant echocardiogram investigation:
 - First line: transthoracic echocardiogram (TTE).

- Please provide relevant clinical details:
 - Symptoms and/or signs.
 - Past medical history of CIED.
 - If positive, microbiology investigative history of:
 - *Staphylococcus aureus* or *Candida* species bloodstream infection.
 - Persistent bloodstream infection with a microorganism typical (or atypical) for CIED infection.
 - For example: “Fever. CIED. Bacteraemic with *Staphylococcus* species. ?CIED infection.”
- Requests are triaged and can be rejected, e.g. a request received without symptoms or signs or differential diagnosis of CIED infection.
- Clinical suspicions of CIED infection and initial TTE findings may warrant further investigation:
 - Second line: transoesophageal echocardiogram (TOE).
 - Indications can include: past medical history of CIED; negative TTE and clinical suspicions remaining high; equivocal TTE and clinical suspicions persisting; positive TTE and clinical suspicions regarding complications.

With regard to TOE, this specialist procedure requires collaboration with cardiology. Specifically, via switchboard, the physicians contact the cardiology registrar on call. The specialty trainee reviews the patient, and then contacts the cardiology consultant performing the next TOE list, regarding ± proceeding with the TOE.

- NB1 TTE and TOE can periodically require repeating:
 - If the initial TTE and TOE are negative, and clinical suspicions remain high.
 - If the initial echocardiograms are positive, and clinical suspicions arise regarding cardiovascular complications.
- NB2 In CIED lead infection, echocardiograms are – in general – positive; revealing lead and/or valve vegetations.

Radiology and nuclear medicine

- If there is no “definite’ CIED/IE” and/or:
 - If there is “possible’ CIED/IE”:
 - Healthcare professionals may consider:
 - Cardiac computed tomography (CT); or
 - Fluorine-18 fluorodeoxyglucose (¹⁸F-FDG) positron emission tomography (PET) CT; or
 - Technetium metastable-99 hexamethylpropylene amine oxime (^{99m}Tc HMPAO) labelled white cell single photon emission computed tomography (SPECT) CT

In collaboration with one of the consultant radiologists with a specialist interest in cardiac imaging for cardiac CT and nuclear medicine for PET CT or SPECT CT.
- With regard to nuclear medicine:
 - First line, in Nottingham, if the patient can be transferred:
 - ¹⁸F-FDG PET CT.
 - Turnaround time approximately 7 days.
 - Second line, in Derby, if the patient cannot be transferred:
 - ^{99m}Tc SPECT CT.
 - Turnaround time approximately 10-14 days.

- Third line, in Derby, if the patient cannot be transferred:
 - Gallium-67 SPECT CT.
 - Turnaround time approximately ≥ 14 days.
- NB Ward doctor to liaise with one of the three radiologists supporting nuclear medicine regarding:
 - The request; and
 - The logistics of the procedure (for example, Atkin's diet for ≥ 72 hours before ^{18}F -FDG PET CT).

Criteria for diagnosis of CIED lead infection and/or infective endocarditis

- The European Heart Rhythm Association (EHRA) outlined, in 2019, International CIED Infection Criteria that enable diagnoses of:
 - "Definite" CIED/IE":
 - 2 major criteria; or
 - 1 major and 3 minor criteria.
 - "Possible" CIED/IE":
 - 1 major and 1 minor criteria; or
 - 3 minor criteria.

Major criteria: microbiology

- (a) Bloodstream infection with a microorganism consistent with CIED lead infection and/or infective endocarditis:
 - "Coagulase-negative Staphylococci, *Staphylococcus aureus*".
- (b) Bloodstream infection with a microorganism consistent with infective endocarditis from 2 sets of blood cultures:
 - "Viridans streptococci, *Streptococcus gallolyticus* (*Streptococcus bovis*), HACEK group, *S. aureus* or
 - Community-acquired enterococci, in the absence of a primary focus."
- (c) Persistent bloodstream infection with a microorganism consistent with infective endocarditis:
 - From blood cultures drawn > 12 hours apart; or
 - From 3 of 3 sets of blood cultures, with the first and last sets drawn > 1 hour apart; or
 - From the majority of ≥ 4 sets of blood cultures, with the first and last sets drawn > 1 hour apart.
- (d) Bloodstream infection with *Coxiella burnetii* from ≥ 1 set of blood cultures; or serological evidence of active Q fever with *Coxiella burnetii* anti-phase I IgG titre $\geq 1:800$.

Major criteria: radiology

- Echocardiogram revealing:
 - (a) Valvular perforation; or
 - (b) Valvular aneurysm; or
 - (c) Lead vegetation; or
 - (d) Valve vegetation; or
 - (e) New partial dehiscence of prosthetic valve; or
 - (f) Intracardiac fistula; or
 - (g) Abscess; or
 - (h) Pseudoaneurysm.
- Cardiac CT revealing:
 - (i) Paravalvular leakage.
- PET CT revealing:

- (j) Accumulation of ^{18}F -FDG in leucocytes and other immune cells in cardiovascular sites (leads, valves, pocket generator) of infection consistent with CIED lead infection and/or infective endocarditis.
- SPECT CT revealing:
 - (k) Accumulation of $^{99\text{m}}\text{Tc}$ HMPAO radiolabelled leucocytes in cardiovascular sites (leads, valves, pocket generator) of infection consistent with CIED lead infection and/or infective endocarditis.

Minor criteria

- (a) Fever (temperature ≥ 38.0 °C).
- (b) Immunological phenomena: Roth spots, Osler nodes, glomerulonephritis, or rheumatoid factor.
- (c) Vascular phenomena: intracranial haemorrhage, conjunctival haemorrhage, Janeway lesions, pulmonary infarcts, mycotic aneurysm, or major arterial emboli.
- (d) Past/Present medical history of predisposing cardiac pathology (e.g. “new onset tricuspid valve regurgitation”) or social history of intravenous drug usage.
- (e) Bloodstream infection without major criteria (a), (b), (c), or (d); or serological evidence of active infection with a microorganism consistent with infective endocarditis; or lead culture of a microorganism consistent with CIED lead infection and/or infective endocarditis.

Treatment

The EHRA states:

- “Definitive treatment of CIED infection is early and complete removal of all parts of the system and antibiotic therapy is to be seen as a complement.”

Medical or surgical intervention¹: explantation of the CIED

- Collaborate with the cardiology consultant regarding potential removal versus possible retention of the CIED.
- Indications for explantation include:
 - Diagnosis of ‘definite’ CIED/IE.
 - Echocardiogram revealing lead or valve vegetation(s).
 - *Staphylococcus aureus* or *Candida* species bloodstream infection:
 - With a CIED in situ:
 - Without a non-cardiovascular system focus of infection; or
 - With recent manipulation of the cardiac device; or
 - With bacteraemia/fungaemia persisting on/recurring after completion of antimicrobial chemotherapy.
 - Bacteraemia, with ≥ 2 sets of blood cultures drawn ≥ 1 hour apart with microorganisms (e.g. coagulase negative staphylococci) consistent with CIED infection:
 - With a CIED in situ;
 - Without a non-cardiovascular system focus of infection; or
 - With recent manipulation of the cardiac device; or
 - With bacteraemia/fungaemia persisting on/recurring after completion of antimicrobial chemotherapy.
- NB If the CIED has been in situ for > 12 months, the nature of the host responses to the cardiac device necessitates referral to a surgical team specialising in removal of chronic, connective tissue coated CIEDs.

- Consider retention of the CIED if:
 - An extensive past medical history, with co-morbidities contraindicating a return to the cath lab/theatre; or
 - A past medical history of a long-standing CIED; or
 - *Staphylococcus aureus* or *Candida* species bloodstream infection:
 - With a CIED in situ:
 - With a non-cardiovascular system focus of infection; or
 - With no recent manipulation of the cardiac device; or
 - With no bacteraemia/fungaemia persisting on/recurring after completion of antimicrobial chemotherapy.
 - Bacteraemia, with ≥ 2 sets of blood cultures drawn ≥ 1 hour apart with microorganisms (e.g. coagulase negative staphylococci) consistent with CIED infection:
 - With a CIED in situ;
 - With a non-cardiovascular system focus of infection; or
 - With no recent manipulation of the cardiac device; or
 - With no bacteraemia/fungaemia persisting on/recurring after completion of antimicrobial chemotherapy.
 - Bacteraemia with a non-cardiovascular system focus of infection.

Medical or surgical intervention²: temporary pacing

- If the past medical history dictates continuous pacing, the cardiologist may contemplate explantation of the device and then cardiac support with:
 - The insertion of a temporary pacing lead; introduced transcutaneously through the venous vasculature (in general, the right internal jugular vein) into the heart; and
 - The attachment of this pacing lead to an external generator; with the temporary generator sited on the neck or back, with an adherent skin dressing maintaining its location.

Medical or surgical intervention³: reimplantation of the CIED

- If returned to the cath lab or taken to theatre for removal of the CIED regarding lead infection with the echocardiogram revealing valve vegetation:
 - Perform blood cultures on the date of removal (NB after removal of the CIED), repeat blood cultures on day 5 after removal, and repeat blood cultures on day 10 after removal:
 - If the blood cultures remain negative on day 14, proceed with reimplantation*.
- If returned to the cath lab or taken to theatre for removal of the CIED regarding lead infection with the echocardiogram revealing lead vegetation only:
 - Perform blood cultures on the date of removal (NB after removal of the CIED):
 - If the blood cultures remain negative after ≥ 72 hours of culture, proceed with reimplantation*.
- If returned to the cath lab or taken to theatre for removal of the CIED regarding lead infection with bacteraemia without echocardiogram vegetation:
 - Perform blood cultures on the date of removal (NB after removal of the CIED):
 - If the blood cultures remain negative after ≥ 72 hours of culture, proceed with reimplantation*.
- * NB The new CIED is inserted contralateral to the old, removed cardiac device.

Empiric antibiotics

- If there are no clinical concerns regarding sepsis (life threatening organ dysfunction caused by a dysregulated host immune response to infection):
 - After blood cultures × 3:

First line	Vancomycin or teicoplanin intravenously, dose as per hospital guidelines , vancomycin target pre dose level 15-20 mg/l, teicoplanin target pre dose level 30-40 mg/l, and Gentamicin 3 mg/kg intravenously 24 hourly (NB maximum of 240 mg), target pre dose trough < 1 mg/l, and Rifampicin 300-600* mg per oral 12 hourly
Second line	Daptomycin 8-10 mg/kg intravenously 24 hourly and Gentamicin 3 mg/kg intravenously 24 hourly (NB maximum of 240 mg), target pre dose trough < 1 mg/l, and Rifampicin 300-600* mg per oral 12 hourly
* Rifampicin 300 mg if creatinine clearance < 30 ml/min, 600 mg if creatinine clearance ≥ 30 ml/min	

- If there are clinical concerns regarding sepsis (life threatening organ dysfunction caused by a dysregulated host immune response to infection) secondary to lead infection:
 - After blood cultures × 3:

First line	Piperacillin tazobactam 4.5 g intravenously 6 hourly and Vancomycin or teicoplanin intravenously, dose as per hospital guidelines , vancomycin target pre dose level 15-20 mg/l, teicoplanin target pre dose level 30-40 mg/l
Second line, if non-immediate without systemic involvement penicillin allergy	Ceftazidime 2 g intravenously 8 hourly and Vancomycin or teicoplanin intravenously, dose as per hospital guidelines , vancomycin target pre dose level 15-20 mg/l, teicoplanin target pre dose level 30-40 mg/l
Third line, if immediate rapidly evolving or non-immediate with systemic involvement penicillin allergy	Ciprofloxacin 400 mg intravenously 8 hourly and Vancomycin or teicoplanin intravenously, dose as per hospital guidelines , vancomycin target pre dose level 15-20 mg/l, teicoplanin target pre dose level 30-40 mg/l

CIED in situ: directed antibiotics (**with susceptibilities**)

- Methicillin susceptible *Staphylococcus* species, **according to susceptibilities**:
 - First line:
 - Flucloxacillin 2 g intravenously 4-6 hourly (6 hourly if ≤ 85 kg; 4 hourly if > 85 kg) **and**
 - [Gentamicin](#) 3 mg/kg intravenously 24 hourly (NB maximum of 240 mg), target pre dose trough < 1 mg/l, **and**
 - Rifampicin 300-600* mg per oral 12 hourly.
 - Second line, [if non-immediate without systemic involvement penicillin allergy](#):
 - Cefuroxime 1.5 g intravenously 8 hourly **and**
 - [Gentamicin](#) 3 mg/kg intravenously 24 hourly (NB maximum of 240 mg), target pre dose trough < 1 mg/l, **and**
 - Rifampicin 300-600* mg per oral 12 hourly.
 - Third line, [if immediate rapidly evolving or non-immediate with systemic involvement penicillin allergy](#):

- Vancomycin or teicoplanin intravenously, [dose as per hospital guidelines](#), vancomycin target pre dose level 15-20 mg/l, teicoplanin target pre dose level 30-40 mg/l, **and**
 - [Gentamicin](#) 3 mg/kg intravenously 24 hourly (NB maximum of 240 mg), target pre dose trough < 1 mg/l, **and**
 - Rifampicin 300-600* mg per oral 12 hourly.
- Methicillin resistant *Staphylococcus* species, **according to susceptibilities**:
 - First line:
 - Vancomycin or teicoplanin intravenously, [dose as per hospital guidelines](#), vancomycin target pre dose level 15-20 mg/l, teicoplanin target pre dose level 30-40 mg/l, **and**
 - [Gentamicin](#) 3 mg/kg intravenously 24 hourly (NB maximum of 240 mg), target pre dose trough < 1 mg/l, **and**
 - Rifampicin 300-600* mg per oral 12 hourly.
 - Second line:
 - Daptomycin 8-10** mg/kg intravenously 24 hourly **and**
 - [Gentamicin](#) 3 mg/kg intravenously 24 hourly (NB maximum of 240 mg), target pre dose trough < 1 mg/l, **and**
 - Rifampicin 300-600* mg per oral 12 hourly.
- *Streptococcus* species¹, **according to susceptibilities**, penicillin MIC ≤ 0.125 mg/l:
 - First line:
 - Benzylpenicillin 1.2 g intravenously 4 hourly.
 - Second line, [if non-immediate without systemic involvement penicillin allergy](#):
 - Ceftriaxone 2 g intravenously 24 hourly.
 - Third line, [if immediate rapidly evolving or non-immediate with systemic involvement penicillin allergy](#):
 - Vancomycin or teicoplanin intravenously, [dose as per hospital guidelines](#), vancomycin target pre dose level 15-20 mg/l, teicoplanin target pre dose level 30-40 mg/l.
- *Streptococcus* species², **according to susceptibilities**, penicillin MIC > 0.125 to 2 mg/l:
 - First line:
 - Benzylpenicillin 2.4 g intravenously 4 hourly **and**
 - [Gentamicin](#) 3 mg/kg intravenously 24 hourly (NB maximum of 240 mg), target pre dose trough < 1 mg/l.
 - Second line, [if non-immediate without systemic involvement penicillin allergy](#):
 - Ceftriaxone 2 g intravenously 24 hourly **and**
 - [Gentamicin](#) 3 mg/kg intravenously 24 hourly (NB maximum of 240 mg), target pre dose trough < 1 mg/l.
 - Third line, [if immediate rapidly evolving or non-immediate with systemic involvement penicillin allergy](#):
 - Vancomycin or teicoplanin intravenously, [dose as per hospital guidelines](#), vancomycin target pre dose level 15-20 mg/l, teicoplanin target pre dose level 30-40 mg/l, **and**
 - [Gentamicin](#) 3 mg/kg intravenously 24 hourly (NB maximum of 240 mg), target pre dose trough < 1 mg/l.
- *Enterococcus* species, **according to susceptibilities**:
 - First line:
 - Amoxicillin 2 g intravenously 4 hourly **and**
 - [Gentamicin](#) 3 mg/kg intravenously 24 hourly (NB maximum of 240 mg), target pre dose trough < 1 mg/l.
 - Second line, if drug history of penicillin allergy:

- Vancomycin or teicoplanin intravenously, [dose as per hospital guidelines](#), vancomycin target pre dose level 15-20 mg/l, teicoplanin target pre dose level 30-40 mg/l, **and**
 - [Gentamicin](#) 3 mg/kg intravenously 24 hourly (NB maximum of 240 mg), target pre dose trough < 1 mg/l.
- *Corynebacterium* species, *Cutibacterium* species, Gram negative bacteria, and fungi:
 - Collaborate with the microbiology team.
- * Rifampicin 300 mg if creatinine clearance < 30 ml/min, 600 mg if creatinine clearance ≥ 30 ml/min.
- ** Final dosage to be tailored to specific parameters of the pathogen (e.g. minimum inhibitory concentration) in collaboration with the microbiology consultant responsible for sterile site investigation or within a cardiology multi-disciplinary meeting.

CIED explanted: directed antibiotics (with susceptibilities)

- Methicillin susceptible *Staphylococcus* species, **according to susceptibilities**:
 - First line:
 - Flucloxacillin 2 g intravenously 4-6 hourly (6 hourly if ≤ 85 kg; 4 hourly if > 85 kg).
 - Second line, [if non-immediate without systemic involvement penicillin allergy](#):
 - Cefuroxime 1.5 g intravenously 8 hourly.
 - Third line, [if immediate rapidly evolving or non-immediate with systemic involvement penicillin allergy](#):
 - Vancomycin or teicoplanin intravenously, [dose as per hospital guidelines](#), vancomycin target pre dose level 15-20 mg/l, teicoplanin target pre dose level 30-40 mg/l, **and**
 - Rifampicin 300-600* mg per oral 12 hourly.
- Methicillin resistant *Staphylococcus* species, **according to susceptibilities**:
 - First line:
 - Vancomycin or teicoplanin intravenously, [dose as per hospital guidelines](#), vancomycin target pre dose level 15-20 mg/l, teicoplanin target pre dose level 30-40 mg/l, **and**
 - Rifampicin 300-600* mg per oral 12 hourly.
 - Second line:
 - Daptomycin 8-10** mg/kg intravenously 24 hourly **and**
 - Rifampicin 300-600* mg per oral 12 hourly.
- *Streptococcus* species¹, **according to susceptibilities**, penicillin MIC ≤ 0.125 mg/l:
 - First line:
 - Benzylpenicillin 1.2 g intravenously 4 hourly.
 - Second line, [if non-immediate without systemic involvement penicillin allergy](#):
 - Ceftriaxone 2 g intravenously 24 hourly.
 - Third line, [if immediate rapidly evolving or non-immediate with systemic involvement penicillin allergy](#):
 - Vancomycin or teicoplanin intravenously, [dose as per hospital guidelines](#), vancomycin target pre dose level 15-20 mg/l, teicoplanin target pre dose level 30-40 mg/l.
- *Streptococcus* species², **according to susceptibilities**, penicillin MIC > 0.125 to 2 mg/l:
 - First line:
 - Benzylpenicillin 2.4 g intravenously 4 hourly **and**

- [Gentamicin](#) 3 mg/kg intravenously 24 hourly (NB maximum of 240 mg), target pre dose trough < 1 mg/l.
 - Second line, [if non-immediate without systemic involvement penicillin allergy](#):
 - Ceftriaxone 2 g intravenously 24 hourly **and**
 - [Gentamicin](#) 3 mg/kg intravenously 24 hourly (NB maximum of 240 mg), target pre dose trough < 1 mg/l.
 - Third line, [if immediate rapidly evolving or non-immediate with systemic involvement penicillin allergy](#):
 - Vancomycin or teicoplanin intravenously, [dose as per hospital guidelines](#), vancomycin target pre dose level 15-20 mg/l, teicoplanin target pre dose level 30-40 mg/l, **and**
 - [Gentamicin](#) 3 mg/kg intravenously 24 hourly (NB maximum of 240 mg), target pre dose trough < 1 mg/l.
- *Enterococcus* species, **according to susceptibilities**:
 - First line:
 - Amoxicillin 2 g intravenously 4 hourly **and**
 - [Gentamicin](#) 3 mg/kg intravenously 24 hourly (NB maximum of 240 mg), target pre dose trough < 1 mg/l.
 - Second line, if drug history of penicillin allergy:
 - Vancomycin or teicoplanin intravenously, [dose as per hospital guidelines](#), vancomycin target pre dose level 15-20 mg/l, teicoplanin target pre dose level 30-40 mg/l, **and**
 - [Gentamicin](#) 3 mg/kg intravenously 24 hourly (NB maximum of 240 mg), target pre dose trough < 1 mg/l.
- *Corynebacterium* species, *Cutibacterium* species, Gram negative bacteria, and fungi:
 - Collaborate with the microbiology team.
- * Rifampicin 300 mg if creatinine clearance < 30 ml/min, 600 mg if creatinine clearance ≥ 30 ml/min.
- ** Final dosage to be tailored to specific parameters of the pathogen (e.g. minimum inhibitory concentration) in collaboration with the microbiology consultant responsible for sterile site investigation or within a cardiology multi-disciplinary meeting.

Duration of antibiotics

- 4-6 weeks, from the date of the last sterile site investigation positive for the causative agent.
- NB Gentamicin ≥ 2 weeks.

Management of CIED lead infection

Background includes CIED; and

- Symptoms/Signs of infective endocarditis; or
- Pyrexia of unknown origin

Investigate

Radiology:

- CXR

Cardiology/Clinical Measurement Department:

- Echocardiogram:
 - TTE ± TOE

AND

Microbiology:

- Blood cultures x 3
- If purulent discharge, fluid MC&S

Blood sciences:

- FBC, CRP, lactate, U&Es, and LFTs

Treatment

Medical or surgical intervention:

- Step 1: explantation of the CIED:
 - Collaborate with the cardiology consultant regarding removal versus retention of the CIED
 - If there is no 'definite' CIED/IE, consider further investigation with nuclear medicine
 - If returned to the cath lab or taken to theatre, pocket swab, tissue sample, and/or lead tip for MC&S
- Step 2: ± temporary pacing
- Step 3: ± reimplantation of the CIED

AND

Antibiotics:

- Step 1: empiric
 - Microbiology full clinical guideline, page 7
- Step 2: directed
 - Microbiology full clinical guideline, pages 7-10

Appendix 1: Gentamicin

Please note the bespoke [gentamicin infective endocarditis prescription chart](#).

Treatment dose	Infective endocarditis: 3 mg/kg IV 24 hourly (NB maximum of 240 mg)
Contraindications	BNF : “myasthenia gravis”
Interactions	Please review the BNF for up-to-date interactions
Common or very common side-effects (please review BNF for uncommon and rare or very rare)	Skin reactions, tinnitus
Important side-effects of note	Vestibular toxicity, ototoxicity, nephrotoxicity
Renal impairment	BNF : “If there is impairment of renal function, the interval between doses must be increased; if the renal impairment is severe, the dose itself should be reduced as well. Excretion of aminoglycosides is principally via the kidney and accumulation occurs in renal impairment. Ototoxicity and nephrotoxicity occur commonly in patients with renal failure”
Therapeutic drug monitoring <ul style="list-style-type: none"> • Recommended • Pre dose • Therapeutic level, trough • Repeat 	<p style="text-align: center;">Yes</p> <p style="text-align: center;">1-2 ml serum, pre dose < 1 mg/l</p> <p style="text-align: center;">Daily, until pre/trough level is within range. Weekly, thereafter</p>
Dose and frequency advice	<p style="text-align: center;">Within the working day, discuss with the ward pharmacist or antimicrobial pharmacist</p> <p style="text-align: center;">Out-of-hours, discuss with the on call pharmacist</p>

In CIED lead infection:

- **Please inform the patient of gentamicin’s known side effects, especially vestibular toxicity, ototoxicity, and nephrotoxicity.**
- Please refer the patient to the audiology department for baseline assessment of hearing, and re-refer if the patient or the physician notes side-effects, for example impaired balance, dizziness, and/or hearing impairment.
- Please monitor the patient’s kidney function \geq twice weekly.
- **If side-effects of vestibular toxicity, ototoxicity, or kidney dysfunction-failure manifest, stopping/withholding gentamicin is recommended.** Please notify the microbiology team if gentamicin is stopped/withheld.

References

- Bennett, J. E., et al.** 2015. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 8th Edition. Elsevier.
- Blomstrom-Lundqvist, C., et al.** 2020. European Heart Rhythm Association (EHRA) international consensus document on how to prevent, diagnose, and treat cardiac implantable electronic device infections-endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), the Latin American Heart Rhythm Society (LAHRS), International Society for Cardiovascular Infectious Diseases (ISCVID) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal.
- Gould, F. K., et al.** 2012. Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: a report of the Working Party of the British Society for Antimicrobial Chemotherapy. Journal of Antimicrobial Chemotherapy.
- Habib, G., et al.** 2023. 2023 ESC Guidelines for the management of endocarditis. European Heart Journal.
- Karchmer, A. W. et al.** 2022. Infections involving cardiac implantable electronic devices: Epidemiology, microbiology, clinical manifestations, and diagnosis. Available at: [Infections involving cardiac implantable electronic devices: Epidemiology, microbiology, clinical manifestations, and diagnosis - UpToDate](#).
- Karchmer, A. W. et al.** 2021. Infections involving cardiac implantable electronic devices: Treatment and prevention. Available at: [Infections involving cardiac implantable electronic devices: Treatment and prevention - UpToDate](#).
- Sandoe, J. A. T., et al.** 2015. Guidelines for the diagnosis, prevention and management of implantable cardiac electronic device infection. Report of a joint Working Party project on behalf of the British Society for Antimicrobial Chemotherapy (BSAC, host organization), British Heart Rhythm Society (BHRS), British Cardiovascular Society (BCS), British Heart Valve Society (BHVS) and British Society for Echocardiography (BSE). Journal of Antimicrobial Chemotherapy.

Document control

Development of guidelines:	Ellie Birnie, Kayleigh Lehal, Dr Peter Slovak
Consultation with:	Lead Antimicrobial Pharmacists, Microbiology Consultant
Version:	2.1
Approval date:	Medicine Division - Oct 2024
Changes from previous version:	Modification of " gentamicin 1 mg/kg intravenously 12 hourly, target pre dose trough < 1 mg/l and target post dose peak 3-5 mg/l" to " gentamicin 3 mg/kg intravenously 24 hourly (NB maximum of 240 mg), target pre dose trough < 1 mg/l". Modification of Appendix 2: gentamicin (removal of post dose peak information). Modification of references to include 2023 ESC Guidelines for the management of endocarditis. Modification of document control to include Ellie Birnie.
Date uploaded:	22/10/2024
Next review date:	January 2026
Key contacts:	Dr Peter Slovak, Microbiology Consultant p.slovak@nhs.net Kayleigh Lehal, Lead Antimicrobial Pharmacist kayleigh.lehal@nhs.net Ellie Birnie, Lead Antimicrobial Pharmacist ellie.birnie1@nhs.net